The EU General Court offers a mixed review of patent settlement agreements in the pharmaceutical sector (Servier)

On 12 December 2018, the General Court (“GC”) once again passed judgment on a number of patent settlement agreements in the pharmaceutical sector. It had already reviewed such agreements in September 2016 when it upheld the decision of the European Commission (the “Commission”) in the Lundbeck case and ruled for the first time that pharmaceutical “pay-for-delay” agreements breach EU competition rules (T-691/14, Servier and Others v. Commission, see VBB on Competition Law, Volume 2016, No. 9). In such agreements, an original pharmaceutical manufacturer pays generics producers to stay out of the market. Background The Commission imposed total fines of € 427.7 million on Servier and

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Peter L'Ecluse, The EU General Court offers a mixed review of patent settlement agreements in the pharmaceutical sector (Servier), 12 December 2018, e-Competitions Bulletin December 2018, Art. N° 88976

Visites 199

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues